TherapeuticsMD Inc
NASDAQ:TXMD
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.7252
2.825
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
TherapeuticsMD Inc
TherapeuticsMD, Inc. operates as a pharmaceutical company. The company is headquartered in Boca Raton, Florida and currently employs 416 full-time employees. The company went IPO on 2001-01-31. Its contraceptive products include ANNOVERA. ANNOVERA (segesterone acetate (SA) and ethinyl estradiol (EE) vaginal system) is a one-year ring-shaped contraceptive vaginal system (CVS) and patient-controlled, procedure-free, reversible prescription contraceptive. Its menopause portfolio includes IMVEXXY and BIJUV. IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy due to menopause. (estradiol and progesterone) capsules is a bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. Its prenatal vitamin products include vitaTrue, vitaPearl, and BocaGreenMD Prena1 True.
TherapeuticsMD, Inc. operates as a pharmaceutical company. The company is headquartered in Boca Raton, Florida and currently employs 416 full-time employees. The company went IPO on 2001-01-31. Its contraceptive products include ANNOVERA. ANNOVERA (segesterone acetate (SA) and ethinyl estradiol (EE) vaginal system) is a one-year ring-shaped contraceptive vaginal system (CVS) and patient-controlled, procedure-free, reversible prescription contraceptive. Its menopause portfolio includes IMVEXXY and BIJUV. IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy due to menopause. (estradiol and progesterone) capsules is a bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. Its prenatal vitamin products include vitaTrue, vitaPearl, and BocaGreenMD Prena1 True.
Revenue Growth: TherapeuticsMD reported Q2 revenue of $28.6 million, up 24% from the same period last year.
Cost Control: Operating expenses declined by 21% year-over-year, reflecting tight expense management and the divestiture of vitaCare.
Debt Reduction: The company repaid $120 million in debt during the quarter, primarily funded by the $142.6 million sale of vitaCare.
ANNOVERA Strength: ANNOVERA sales and prescriptions showed strong growth after resolving inventory shortages and receiving FDA approval for expanded supply.
Strategic Alternatives: A planned sale to EW Healthcare Partners fell through due to insufficient shareholder support; management is now exploring refinancing and other strategic options.
Liquidity Actions: TherapeuticsMD secured a $15 million investment and extended debt maturity to support near-term operations.
